Market closed · After hours · 4:04 PM ET
Last update: Sep 9, 2026, 3:53 PM ET
Johnson & Johnson
$267.19 0.72% today
After Hours

Why Johnson & Johnson (JNJ) stock moved

Updated Sep 9, 2026

Johnson & Johnson (JNJ) shares fell 0.7% to $267.19 as of September 9, 2026, a slight decline from the prior close of $269.12. BestStocks flagged the session as a material change for JNJ. The move is tied to company news. Below, we break down what changed for JNJ, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

Company News

JNJ presents Phase 3 CAPLYTA data for bipolar mania and advances SPRAVATO schizophrenia research at Psych Congress. Positive Phase 3 data expands CAPLYTA's addressable market across mood disorders; strengthens neuropsychiatry pipeline competitiveness.

This summary describes the catalyst and move as first detected on Sep 8, 2026, 10:11 AM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
NewsSector-Wide MoveWeak confidence
Rel. volume
0.5×
Below Avg
Vs peers
Top 6 of 7 peers
Underperforming
Market cap
$643.9B
New York Stock Exchange
Analyst target
$285
+6.6% vs price
Price chart
Aug 10 – Sep 9
NNNNNNNNN$259$269$279Aug 10Aug 17Aug 25Sep 1Sep 9
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Johnson & Johnson investors

For Johnson & Johnson investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum. Weighing against that: Negative session, down 0.7%; JNJ fell 2.57% to $251.87 intraday despite posting first-quarter earnings that beat forecasts and raising full-year guidance. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in JNJ's fundamentals. Wall Street's consensus price target sits at $284.79, implying +6.6% upside from $267.19. BestStocks rates the overall signal quality weak (26/100). With earnings roughly 34 days out, the next report is the most likely near-term test of the move.

JNJ price reaction

JNJ last traded at $267.19, down $1.93 (-0.72%) from the previous close of $269.12. The session traded on 0.5× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median -0.0% over the same stretch, leaving JNJ behind the group by 0.7 points. Over the past month the stock has ranged between $259.80 and $278.43, and it currently sits about 40% of the way up that band.

Bullish and bearish analyst opinions on Johnson & Johnson (JNJ)

The consensus analyst price target on Johnson & Johnson (JNJ) is $284.79, 6.6% above the recent $267.19. Over the past 90 days analysts logged 0 upgrades, 14 maintains, and 0 downgrades. Here is how the bullish and bearish cases on JNJ line up.

The bullish case

  • Wall Street's consensus price target of $284.79 implies +6.6% upside from $267.19.
  • The Street's most bullish target is $320.00 (+19.8%).
  • Positive price momentum.

The bearish case

  • The most bearish analyst target is $255.00 (-4.6%).
  • Negative session, down 0.7%.
  • JNJ fell 2.57% to $251.87 intraday despite posting first-quarter earnings that beat forecasts and raising full-year guidance.
Bull vs bear balanceBearish Shift
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Sep 9, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $285+6.6%
= 14 maintains
UBS maintained Buy · 2026-09-02
SEC filings watch
8-K2026-08-04
Material event — review for impact
high
8-K2026-07-29
Material event — review for impact
high
8-K2026-07-28
Material event — review for impact
high
10-Q2026-07-23
Quarterly financial results
medium
Peer context
JNJ-0.7%
LLY+0.0%
UNH-1.9%
PFE-0.0%
ABBV+0.9%
MRK-0.6%

Previous notable changes for JNJ

News2026-09-07
EFG International AG reduced its JNJ stake by 5.5%, selling 22,008 shares in Q2.
News2026-09-04-1.1%
JNJ maintains 64-year dividend growth streak despite major drug facing intense competitive pressure.
News2026-09-03+1.2%
EP Wealth Advisors increased JNJ stake by 15.9% to 708,767 shares through additional purchases.
News2026-09-02+1.5%
Johnson & Johnson will present at the Deutsche Bank 2026 Healthcare Summit on September 17th.
Upcoming catalysts & outlook
Next earnings
2026-10-13 (est.)
in 34 days
10-Q Filing (est.)
2026-10-22
Medium impact
Thesis shift
Bearish Shift
bearish signal
Risk level
Medium
from change events

Frequently asked questions about JNJ

Why did Johnson & Johnson (JNJ) stock move?

JNJ fell 0.7% to $267.19. The move coincided with the context summarized above, which BestStocks classifies as a sector-wide move, though no single company-specific catalyst was independently confirmed.

How much did JNJ stock fall?

JNJ lost 0.72% ($1.93) versus the prior close of $269.12, last trading at $267.19 on 0.5× average volume.

When is Johnson & Johnson's next earnings date?

JNJ's next earnings report is estimated for 2026-10-13 — about 34 days away.

What is the analyst price target for JNJ?

The consensus analyst price target for JNJ is $284.79, about 6.6% above the current $267.19. Over the past 90 days, analysts recorded 0 upgrades, 14 maintains, and 0 downgrades.

Is the JNJ move company-specific or sector-wide?

BestStocks classifies it as a sector-wide move: the peer group moved a median -0.0% against JNJ's -0.7%. JNJ ranks top 6 of 7 peers.

How BestStocks tracks JNJ

This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for JNJ, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 9, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataCompany news feedsSEC EDGAR filingsAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.